The long-term vision for GrafCare includes expanding into global markets, particularly in Southeast Asia and the Middle East, regions with significant transplant populations
GOQii has joined forces with Acrannolife Genomics to launch the GrafCare Program. This initiative leverages advanced genomic diagnostics, artificial intelligence (AI), and personalised health monitoring to redefine post-transplant care for organ recipients in India.
Post-transplant care is a critical yet underserved segment in healthcare. To address the unique challenges faced by transplant recipients, the GrafCare Program combines Acrannolife’s patented Trunome test with GOQii’s smart health ecosystem. This integration offers early detection, real-time health monitoring, and tailored support to enhance patient outcomes and quality of life.
Acrannolife’s US-patented Trunome test is a non-invasive blood test that identifies early signs of organ rejection or infection. Powered by advanced genomic research and AI, the test provides clinicians with precise, actionable insights to intervene before complications escalate. Patients receive a GOQii Smart Vital Device, which tracks vital parameters such as heart rate, blood pressure, and oxygen levels in real time. AI-driven predictive analytics assess patient data to generate early alerts and personalised recommendations, enabling proactive care. The program provides access to nutritionists and counselors who design customised recovery plans tailored to each patient’s genetic profile and health data. A focus on preventive care helps patients manage long-term health while reducing reliance on reactive interventions. To make advanced care accessible, the program offers interest-free loans for up to one year, along with discounts on immunosuppressants and free diagnostic tests such as Tacrolimus and kidney/liver function tests.
Vishal Gondal, Founder & CEO, GOQii said, “This is more than a health program; it’s a lifeline for transplant recipients. With GrafCare, we’re harnessing the power of AI and genomics to empower patients and clinicians alike, offering a new level of care that was previously unattainable.”
Agragesh Ramani, Co-founder, Acrannolife Genomics said, “Having personally experienced the transplant journey within my own family, I understand the emotional and physical challenges patients face. The GrafCare Program, powered by our US-patented Trunome test, offers early and accurate detection of organ rejection, giving patients the best chance to protect their graft. Our goal is to provide the highest level of care, so transplant recipients can focus on healing and living a full, healthy life without the added worry of their health or finances.”